Disclosed herein is the use of a compound of formula (1), wherein the variables are defined in the specification, in the treatment of an inflammatory disorder wherein the inflammatory disorder is mediated by one or more inflammatory cytokines selected from Tumour Necrosis Factor-alpha (TNF-&alpha；), interferon-&gamma； (IFN- &gamma；) and interleukins (IL-1&bgr；, IL-2, IL-6 and IL-8). In one embodiment the compound is (3Z,5E,13E,15E)-18-((6E,10E)-3,9-dihydroxy-4,8-dimethyl-5-oxododeca-6,10-dien-2-yl)-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyloxacyclooctadeca-3,5,13,15-tetraen-2-one.
